Photographer: Daniel Acker/Bloomberg

Mylan’s Settlement With DOJ Not Tough Enough, Senator Says

  • Connecticut’s Blumenthal calling for criminal inquiry
  • Lawmaker says settlement is ‘inadequate,’ unfair to taxpayers

Mylan NV’s $465 million settlement with the U.S. Department of Justice over Medicaid rebates for its EpiPen allergy shot is a “sweetheart deal,” and the company should face a criminal investigation, Senator Richard Blumenthal said Wednesday.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.